OptimizeRx Corp (OPRX): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 16:06 ET
- Event date
- 2026-11-11
- Accession no.
- 0001448431-26-000022
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
OptimizeRx reports third-quarter results and updates 2026 revenue guidance
OptimizeRx reported Q3 2026 revenue of $21.6 million, down 17%, and GAAP net income of $1.2 million, compared to $0.8 million in Q3 2025. The company updated 2026 revenue guidance to $87-$93 million and left adjusted EBITDA guidance unchanged at $21-$25 million.
- Q3 2026 revenue decreased 17% to $21.6 million, compared to $26.1 million in Q3 2025.
- Q3 2026 GAAP net income was $1.2 million, or $0.06 per basic and diluted share.
- Q3 2026 adjusted EBITDA was $6.3 million, compared to $5.1 million in Q3 2025.
- Repaid $9.3 million in debt principal since June 30, 2026, reducing current outstanding principal to $10.4 million.
earningsguidancedebt
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | oprx-20261111.htm |
| EX-99.1 | EX-99.1 | oprxq32026earningsrelease.htm |
| EX-99.2 | EX-99.2 | ex992transcript.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.